论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yang LP, Wang ZX, He MM, Wu HX, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH
Received 4 December 2018
Accepted for publication 25 March 2019
Published 2 May 2019 Volume 2019:11 Pages 3993—4003
DOI https://doi.org/10.2147/CMAR.S197052
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 5
Editor who approved publication: Dr Antonella D'Anneo
Background: The
benefit of palliative gastrectomy for patients with metastatic gastric cancer
(mGC) is controversial, and suitable candidates for surgery and treatment
strategies remain unclear. The present study aimed to investigate the efficacy
of palliative gastrectomy plus chemotherapy among patients with mGC and to
identify the potential patients for such treatment using real-world data.
Methods: A dataset
of 236 patients with mGC diagnosed at the Sun Yat-Sen University Cancer Center
from January 1, 2006 to December 31, 2012 were analyzed retrospectively. The
cohort comprised 80 patients who had palliative gastrectomy plus chemotherapy
(SC) and 156 patients who had chemotherapy only (CO). Propensity score matching
(PSM) was employed to minimize the influence of confounders.
Results: The
median overall survival of the SC group was significantly better than that of
the CO group (Before PSM: 17.0 months vs 12.0 months, P =0.038; after PSM:
17.0 months vs 13.0 months, P =0.017). In the
multivariate analysis, SC (Before PSM: hazard ratio (HR) =0.68, P =0.023; after PSM:
HR =0.64, P =0.021) was favored for better survival after
adjustment for sex, age, year of diagnosis, primary tumor location, and tumor
grade. Total gastrectomy (P =0.026) was associated with worse survival for the SC
group. The significant survival advantage of SC over CO was retained in
patients with single organ metastasis (P =0.016), peritoneal seedings (P =0.039), and those
receiving taxane-based chemotherapy (P =0.011).
Conclusion: SC could
improve the overall survival of patients with mGC as compared with CO. The
chemotherapy regimen and type of resection were proven to influence efficacy.
Patients who received taxane-based regimens might be suitable for palliative
gastrectomy.
Keywords: first-line
chemotherapy, metastatic gastric cancer, palliative gastrectomy, propensity
score matching, survival